LG Chem has applied for the marketing authorization of a combination drug that combines the DPP-4 diabetes treatment ‘Zemiglo (gemigliptin)’ with an SGLT-2 class inhibitor to the Ministry of Food and Drug Safety.

With the new application, whether Zemiglo, one of the most successful locally developed novel drugs, will continue on its success with this new combination therapy is raising attention.

According to the industry on the 7th, LG Chem recently applied for the marketing authorization of its dapagliflozin+gemigliptin combination therapy. The product name is known to be ‘Zemidapa,’ coined using the first letters of the two ingredients. LG Chem trademarked the name to the Korea In